- Current Issue
SIGN IN to access Harper’s Magazine
ALERT: Usernames and passwords from the old Harpers.org will no longer work. To create a new password and add or verify your email address, please sign in to customer care and select Email/Password Information. (To learn about the change, please read our FAQ.)
Four years ago, a group of lawmakers and aides crafted Medicare Part D, the prescription drug program for seniors that has produced billions of dollars of profits for pharmaceutical companies.
Today, at least 25 of those key players are back, but this time they’re lobbyists, trying to persuade their former colleagues to protect the lucrative system during the health care reform negotiations.
The role of big players like Billy Tauzin — the former Republican representative from Louisiana who is now president of PhRMA, the drug industry’s lobbying group — has been long understood. But a ProPublica analysis shows that the drug industry’s position is also being promoted by other foot soldiers from the Part D legislative process, from committee aides to top Bush administration officials.
More from Ken Silverstein:
Ratio of the number of cicada eggs per square mile of southern New Jersey to the number of stars in the Milky Way:
Jeffrey Lockwood, University of Wyoming (Laramie)/American Museum of Natural History (N.Y.C.)
A Singaporean company unveiled Kissenger, a pair of plastic lips mounted on a large plastic egg, which transmits real-time interactive kisses to a distant lover. “I am not interested in the sexual uses for it,” said the device’s inventor. “We’ve taken several steps to minimize the creepiness.”
The practice of sexualized eyeball licking was causing conjunctivitis in Japanese sixth graders.
Subscribe to the Weekly Review newsletter. Don’t worry, we won’t sell your email address!